← All Posts
CPR
Catalyst Pharmaceuticals, Inc.
July 09, 2026
•
Author: Phil Ratcliff
•
CPRX
| Item |
Proposal |
Vote |
| 1 |
To adopt the Agreement and Plan of Merger (the “Merger Agreement”), dated May 6, 2026, by and among Catalyst Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Angelini Pharma S.p.A., an Italian Societa per azioni (“Angelini Pharma”) and Angelini Cielo Inc., a Delaware corporation and wholly owned subsidiary of Angelini Pharma (“Merger Sub”), pursuant to the terms of which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Angelini Pharma. |
✓ For(3.271)
|
| 2 |
To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to the Company's named executive officers that is based on or otherwise relates to the Merger and/or the other transactions contemplated by the Merger Agreement. |
✓ For(3.271)
|
| 3 |
To approve the adjournment of the Special Meeting to a later date or dates as provided in the Merger Agreement, if necessary or appropriate, to solicit additional votes if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting. |
✓ For(3.271)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial